Stoke Therapeutics
STOK
107 hedge funds and large institutions have $369M invested in Stoke Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 12 closing their positions.
346% more call options, than puts
Call options by funds: $183K | Put options by funds: $41K
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 105 → 107 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.07% less ownership
Funds ownership: 107.24% → 102.17% (-5.1%)
31% less capital invested
Capital invested by funds: $533M → $369M (-$164M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$7.69M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.03M |
| 3 |
RI
RTW Investments
New York
|
+$2.28M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$2.08M |
| 5 |
BlackRock
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.77M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$4.87M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.64M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.55M |
STOK Hedge Fund Activity: Q4 2022 in Review
107 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2022, worth a combined $369M — down 31% from $533M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new STOK positions and 12 closed out — a net gain of 2 holders — while 44 added to existing stakes and 33 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $7.69M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $11.4M sold.
- 107 institutional investors held Stoke Therapeutics (STOK) as of Q4 2022, up from 105 in Q3 2022.
- Funds reported $369M of Stoke Therapeutics stock for Q4 2022, down 31% quarter-over-quarter.
- 14 funds opened new Stoke Therapeutics positions in Q4 2022 and 12 closed out, a net change of +2 holders.
- The largest Stoke Therapeutics buyer in Q4 2022 was Baker Bros. Advisors, an estimated $7.69M added.
- The largest Stoke Therapeutics seller in Q4 2022 was Avidity Partners Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2022.